{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:53:31Z","timestamp":1793116411978,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118850","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:18:21Z","timestamp":1765495101000},"page":"118850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Chiglitazar, a PPAR pan-agonist: Impacts on type 2 diabetes mellitus and multi-system metabolic regulation \u2013 A review"],"prefix":"10.1016","volume":"193","author":[{"given":"Ee","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-3904","authenticated-orcid":false,"given":"Xiqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10467","key":"10.1016\/j.biopha.2025.118850_bib1","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118850_bib2","doi-asserted-by":"crossref","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1900\/RDS.2007.4.13","article-title":"Genes, diet and type 2 diabetes mellitus: a review","volume":"4","author":"Dedoussis","year":"2007","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.biopha.2025.118850_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0901-x","article-title":"Environmental\/lifestyle factors in the pathogenesis and prevention of type 2 diabetes","volume":"15","author":"Kolb","year":"2017","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118850_bib5","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0006-2952(99)00191-4","article-title":"Insulin resistance and antidiabetic drugs","volume":"58","author":"Bailey","year":"1999","journal-title":"Biochem Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002026","article-title":"Risks and population burden of cardiovascular diseases associated with diabetes in China: a prospective study of 0.5 million adults","volume":"13","author":"Bragg","year":"2016","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.biopha.2025.118850_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2013.02.035","article-title":"Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients","volume":"126","author":"Ji","year":"2013","journal-title":"Am. J. Med"},{"issue":"9","key":"10.1016\/j.biopha.2025.118850_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091125","article-title":"From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments","volume":"17","author":"Cabr\u00e9","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest"},{"issue":"23","key":"10.1016\/j.biopha.2025.118850_bib11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib13","first-page":"973","article-title":"Evolution of peroxisome proliferator-activated receptor agonists","volume":"41","author":"Chang","year":"2007","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.biopha.2025.118850_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/546548","article-title":"In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist","volume":"2012","author":"He","year":"2012","journal-title":"PPAR Res"},{"key":"10.1016\/j.biopha.2025.118850_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2840-4-14","article-title":"Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons","volume":"4","author":"Tenenbaum","year":"2005","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/ijms19030913","article-title":"PPAR\u03b2\/\u03b4: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1050-1738(00)00077-3","article-title":"PPAR signaling in the control of cardiac energy metabolism","volume":"10","author":"Barger","year":"2000","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.biopha.2025.118850_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118850_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/01.ATV.18.2.272","article-title":"RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo","volume":"18","author":"Mukherjee","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118850_bib21","doi-asserted-by":"crossref","first-page":"E270","DOI":"10.1152\/ajpendo.2001.280.2.E270","article-title":"A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle","volume":"280","author":"Minnich","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2025.118850_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmet.2005.01.006","article-title":"A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes","volume":"1","author":"Finck","year":"2005","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107143","article-title":"Selective activation of PPAR\u03b1 maintains thermogenic capacity of beige adipocytes","volume":"26","author":"Egusa","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2025.118850_bib24","doi-asserted-by":"crossref","first-page":"1029818","DOI":"10.3389\/fimmu.2022.1029818","article-title":"Sebaceous immunobiology \u2013 skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations","volume":"13","author":"Zouboulis","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tips.2023.11.004","article-title":"PPAR agonists for the treatment of neuroinflammatory diseases","volume":"45","author":"Titus","year":"2024","journal-title":"Trends Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.M400400-JLR200","article-title":"Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1","volume":"46","author":"van der Veen","year":"2005","journal-title":"J. Lipid Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/me.2004-0088","article-title":"Be fit or be sick: peroxisome proliferator-activated receptors are down the road","volume":"18","author":"Desvergne","year":"2004","journal-title":"Mol. Endocrinol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2337\/db10-0704","article-title":"Activation of peroxisome proliferator\u2013activated receptor-\u03b2\/-\u03b4 (PPAR-\u03b2\/-\u03b4) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6\u2013stimulated adipocytes","volume":"60","author":"Serrano-Marco","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.biopha.2025.118850_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pharmthera.2009.06.011","article-title":"Emerging roles of peroxisome proliferator-activated receptor-beta\/delta in inflammation","volume":"124","author":"Bishop-Bailey","year":"2009","journal-title":"Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1124\/jpet.106.115758","article-title":"Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo","volume":"320","author":"Iwashita","year":"2007","journal-title":"J. Pharm. Exp. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2025.118850_bib31","first-page":"4293","article-title":"Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle","volume":"85","author":"Lapsys","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/818945","article-title":"Cross-talk between PPAR\u03b3 and insulin signaling and modulation of insulin sensitivity","volume":"2009","author":"Leonardini","year":"2009","journal-title":"PPAR Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib33","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2174\/1381612823666161118145850","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: focus on atherosclerosis","volume":"23","author":"Ivanova","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118850_bib35","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/oby.2006.178","article-title":"Decreased expression of adipogenic genes in obese subjects with type 2 diabetes","volume":"14","author":"Dubois","year":"2006","journal-title":"Obes. (Silver Spring)"},{"issue":"11","key":"10.1016\/j.biopha.2025.118850_bib36","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR gamma gene expression by nutrition and obesity in rodents","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J. Clin. Invest"},{"issue":"38","key":"10.1016\/j.biopha.2025.118850_bib37","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-\u03b1 down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118850_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.physiol.66.032802.154710","article-title":"Ligand control of coregulator recruitment to nuclear receptors","volume":"67","author":"Nettles","year":"2005","journal-title":"Annu Rev. Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118850_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nri912","article-title":"Emerging roles of PPARs in inflammation and immunity","volume":"2","author":"Daynes","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118850_bib40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","article-title":"Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms","volume":"28","author":"Straus","year":"2007","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118850_bib41","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2025.118850_bib43","doi-asserted-by":"crossref","first-page":"5314187","DOI":"10.1155\/2020\/5314187","article-title":"To probe full and partial activation of human peroxisome proliferator-activated receptors by pan-agonist chiglitazar using molecular dynamics simulations","volume":"2020","author":"Sullivan","year":"2020","journal-title":"PPAR Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11596-023-2760-3","article-title":"Advances in studies of chiglitazar sodium, a novel PPAR pan-agonist, for the treatment of type 2 diabetes mellitus","volume":"43","author":"Zhang","year":"2023","journal-title":"Curr. Med. Sci."},{"issue":"7365","key":"10.1016\/j.biopha.2025.118850_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118850_bib46","doi-asserted-by":"crossref","first-page":"4313561","DOI":"10.1155\/2017\/4313561","article-title":"Chiglitazar preferentially regulates gene expression via configuration-restricted binding and phosphorylation inhibition of PPAR","volume":"2017","author":"Pan","year":"2017","journal-title":"PPAR Res"},{"issue":"15","key":"10.1016\/j.biopha.2025.118850_bib47","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"issue":"15","key":"10.1016\/j.biopha.2025.118850_bib48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s13300-025-01708-9","article-title":"Evaluation of the regulatory effect of the pan-PPAR agonist chiglitazar on the dawn phenomenon","volume":"16","author":"Li","year":"2025","journal-title":"Diabetes Ther."},{"issue":"11","key":"10.1016\/j.biopha.2025.118850_bib50","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1111\/dom.70009","article-title":"Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)","volume":"27","author":"Gao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"25","key":"10.1016\/j.biopha.2025.118850_bib51","first-page":"31","article-title":"Clinical efficacy and safety of chiglitazar sodium combined with insulin aspart 30 injection in the treatment of patients with diabetes mellitus type 2","volume":"31","author":"Wang","year":"2024","journal-title":"China Mod. Med."},{"issue":"18","key":"10.1016\/j.biopha.2025.118850_bib52","first-page":"99","article-title":"Clinical study of chiglitazar combined with recombinant human insulin in the treatment of type 2 diabetes mellitus and its effect on fat factors","volume":"17","author":"Huang","year":"2024","journal-title":"Clin. Ration. Drug Use"},{"issue":"07","key":"10.1016\/j.biopha.2025.118850_bib53","first-page":"21","article-title":"Clinical study of sitaglitat sodium combined with degu asparton insulin in the treatment of type 2 diabetes mellitus","volume":"27","author":"Duan","year":"2024","journal-title":"Diabetes N. World"},{"key":"10.1016\/j.biopha.2025.118850_bib54","doi-asserted-by":"crossref","DOI":"10.37349\/edd.2025.100590","article-title":"PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD","volume":"4","author":"Lonardo","year":"2025","journal-title":"Explor. Dig. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib55","first-page":"334","article-title":"Efficacy and safety of chiglitazar in type 2 diabetes: a multi-center, randomized, double-blind, and parallel group clinical trial","volume":"11","author":"Xiaofeng","year":"2019","journal-title":"Chin. J. Diabetes Mellit."},{"issue":"10","key":"10.1016\/j.biopha.2025.118850_bib56","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4239\/wjd.v14.i10.1573","article-title":"Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: a meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"World J. Diabetes"},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2016-0059","article-title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-\u03b1","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib58","article-title":"Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD \u2013 reconciling the present with the past","volume":"3","author":"Ayonrinde","year":"2021","journal-title":"JHEP Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118850_bib59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.21037\/atm-20-3760","article-title":"Non-alcoholic fatty liver diseases: current challenges and future directions","volume":"9","author":"Roeb","year":"2021","journal-title":"Ann. Transl. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib60","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1038\/s41598-025-91312-5","article-title":"Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021","volume":"15","author":"Guo","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118850_bib61","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","author":"Eslam","year":"2025","journal-title":"Hepatol. Int"},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030590","article-title":"Hepatocyte injury and hepatic stem cell niche in the progression of non-alcoholic steatohepatitis","volume":"9","author":"Overi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118850_bib63","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res"},{"key":"10.1016\/j.biopha.2025.118850_bib64","article-title":"Chiglitazar, the first pan-PPAR agonist approved globally, shows potential to treat metabolic dysfunction\u2013associated steatohepatitis in vitro and in vivo","author":"Deng","year":"2024","journal-title":"Res. Sq. Prepr."},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101680","article-title":"The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study","volume":"51","author":"Tan","year":"2025","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2025.118850_bib66","doi-asserted-by":"crossref","unstructured":"Sun, Y., et al., Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase II, randomized, double-blind, placebo-controlled study. Hepatology, 9900: p. 10.1097\/HEP.0000000000001475. doi:http:\/\/dx.doi.org\/10.1097\/hep.0000000000001475.","DOI":"10.1097\/HEP.0000000000001475"},{"issue":"17","key":"10.1016\/j.biopha.2025.118850_bib67","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib68","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","article-title":"Ceramides in insulin resistance and lipotoxicity","volume":"45","author":"Summers","year":"2006","journal-title":"Prog. Lipid Res"},{"issue":"11","key":"10.1016\/j.biopha.2025.118850_bib70","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2337\/diabetes.50.11.2563","article-title":"Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state","volume":"50","author":"Teruel","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib71","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00033.2003","article-title":"Mechanisms of the free fatty acid-induced increase in hepatic glucose production","volume":"284","author":"Lam","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib72","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.2337\/diabetes.53.2007.S119","article-title":"Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes","volume":"53","author":"Robertson","year":"2004","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib73","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2337\/diabetes.51.3.662","article-title":"Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic versus normoglycemic rats","volume":"51","author":"Briaud","year":"2002","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2025.118850_bib74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.bjp.0706745","article-title":"The PPARalpha\/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats","volume":"148","author":"Li","year":"2006","journal-title":"Br. J. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.118850_bib75","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1161\/HYPERTENSIONAHA.122.19912","article-title":"High HDL (high-density lipoprotein) cholesterol increases cardiovascular risk in hypertensive patients","volume":"79","author":"Trimarco","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib76","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131491","article-title":"Structure-function relationships of HDL in diabetes and coronary heart disease","volume":"5","author":"Cardner","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib77","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1463-1326.2008.01012.x","article-title":"Reverse cholesterol transport in type 2 diabetes mellitus","volume":"11","author":"Tan","year":"2009","journal-title":"Diabetes Obes. Metab."},{"issue":"19","key":"10.1016\/j.biopha.2025.118850_bib78","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118850_bib79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-90-481-8622-8_7","article-title":"High density lipoprotein structure-function and role in reverse cholesterol transport","volume":"51","author":"Lund-Katz","year":"2010","journal-title":"Subcell. Biochem"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib80","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCULATIONAHA.106.667428","article-title":"3rd, Lipid management to reduce cardiovascular risk: a new strategy is required","volume":"117","author":"Superko","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.biopha.2025.118850_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/biomedicines10040829","article-title":"Small dense LDL: scientific background, clinical relevance, and recent evidence \u2013 still a risk even with \u2018normal\u2019 LDL-C levels","volume":"10","author":"Superko","year":"2022","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.biopha.2025.118850_bib82","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.3390\/jcm14144945","article-title":"HDL function versus small dense LDL: cardiovascular benefits and implications","volume":"14","author":"Stoicescu","year":"2025","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib83","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11886-002-0113-6","article-title":"Dyslipidemia of the metabolic syndrome","volume":"4","author":"Ruotolo","year":"2002","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.biopha.2025.118850_bib84","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2025.118850_bib85","article-title":"Promotive effect of transdermal administration of chiglitazar on wound healing in diabetic mice","author":"Huang","year":"2023","journal-title":"Bengbu Med. Coll."},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13048-024-01554-6","article-title":"Chiglitazar ameliorates dehydroepiandrosterone-induced polycystic ovary syndrome in rats","volume":"17","author":"Zhao","year":"2024","journal-title":"J. Ovarian Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41598-024-51210-8","article-title":"Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118850_bib88","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s40164-024-00589-1","article-title":"Chiglitazar diminishes the Warburg effect through PPAR\u03b3\/mTOR\/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia","volume":"13","author":"Duan","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118850_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215997","article-title":"Therapeutic inhibition of PPAR\u03b1-HIF1\u03b1-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia","volume":"554","author":"Zhou","year":"2023","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.biopha.2025.118850_bib90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40261-019-00779-4","article-title":"Pharmacokinetics, safety and tolerability of chiglitazar, a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist, in healthy Chinese volunteers: a phase I study","volume":"39","author":"Xu","year":"2019","journal-title":"Clin. Drug Invest."},{"issue":"2","key":"10.1016\/j.biopha.2025.118850_bib91","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/cpdd.1198","article-title":"Pharmacokinetic interaction of chiglitazar with CYP3A4 inducer or inhibitor: an open-label, sequential crossover, self-control, 3-period study in healthy Chinese volunteers","volume":"12","author":"Yuan","year":"2023","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"7","key":"10.1016\/j.biopha.2025.118850_bib92","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cpdd.668","article-title":"Study on drug-drug interactions between chiglitazar, a novel PPAR pan-agonist, and metformin hydrochloride in healthy subjects","volume":"8","author":"Yi","year":"2019","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118850_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104318","article-title":"Drugs targeting peroxisome proliferator-activated receptors","volume":"30","author":"Xie","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118850_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2021.104723","article-title":"The pleiotropic peroxisome proliferator activated receptors: regulation and therapeutics","volume":"124","author":"Dixit","year":"2022","journal-title":"Exp. Mol. Pathol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:16:40Z","timestamp":1777015000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":94,"alternative-id":["S0753332225010443"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118850","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chiglitazar, a PPAR pan-agonist: Impacts on type 2 diabetes mellitus and multi-system metabolic regulation \u2013 A review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118850"}}